BioSpace News Archive

Kaiser Permanente has announced that Israel Rocha has been named regional president of the health system’s Mid-Atlantic region.

Vaxcyte, Inc. announced that Company management will participate in fireside chats and host one-on-one meetings at the following investor conferences.

Recludix Pharma announced that in a presentation given at the 7th Annual Dermatology Drug Development Summit.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Monday, November 6, 2023 at 4:30 p.m. EDT.

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced three presentations at the upcoming 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, California.

Spero Therapeutics, Inc. announced that on October 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 65,000 restricted stock unit awards to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the company will host a conference call and webcast on November 7, 2023 at 4:30 pm ET to provide a business update and report second quarter 2023 financial results.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2023 on Monday, November 6, 2023, after market close.

DBV Technologies, a clinical-stage biopharmaceutical company, announced the receipt of written feedback from the U.S. Food and Drug Administration regarding the remaining study design elements for the COMFORT supplemental safety studies.